Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022

Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) will host a conference call on August 4, 2022, at 8:30 a.m. ET to discuss its financial results for Q2 2022, which ended on June 30, 2022. Participants can access the call by dialing 1-833-634-2601 or 1-412-902-4113 for international callers. A live audio webcast will also be available on the company's investor website. A replay will be accessible for seven days following the event. Amicus focuses on developing therapies for rare metabolic diseases and has a commitment to a robust pipeline of innovative medicines.

Positive

• Company is committed to advancing a robust pipeline of medicines for rare diseases.
• Focus on patient-centered therapies highlights strong market positioning.

Negative

• None.

PHILADELPHIA, July 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2022.

Interested participants and investors may access the conference call by dialing 1-833-634-2601 (U.S. Toll Free) or 1-412-902-4113 (International). A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.

A replay of the call will be available for seven days beginning two hours after the conclusion of the event. Access numbers for this replay are 1-877-344-7529 (U.S. Toll Free), 1-855-669-9658 (Canada Toll Free), and 1-412-317-0088 (International); Access Code: 3033146.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G

FAQ

What date is the Amicus Therapeutics conference call scheduled for?

The conference call is scheduled for August 4, 2022.

How can I access the Amicus Therapeutics Q2 2022 financial results?

You can access the results through the conference call by dialing 1-833-634-2601 or via the live audio webcast on the company's investor website.

What is the focus of Amicus Therapeutics?

Amicus Therapeutics focuses on developing novel medicines for rare metabolic diseases.

How long will the replay of the conference call be available?

The replay will be available for seven days after the event.